A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Sihai Dave Zhao(Massachusetts Eye and Ear Infirmary), Sarah Riley(Dana-Farber Cancer Institute), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), John R. Clark(Harvard University), Zachary Jaffa(Brigham and Women's Hospital), Anne O’Neill(International Breast Cancer Study Group), Douglas R. Adkins(Washington University in St. Louis)
Cited by 59
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926